Bone tissue engineering has emerged as a promising alternative therapy for patients who suffer bone fractures or defects caused by trauma, congenital diseases or tumours. However, the reconstruction of bone defects combined with osteoporosis remains a great challenge for clinicians and researchers. Based on our previous study, Ca–Si-based bioceramics (MSCs) showed enhanced bone formation capabilities under normal conditions, and strontium was demonstrated to be therapeutic in promoting bone quality in osteoporosis patients. Therefore, in the present study, we attempted to enlarge the application range of MSCs with Sr incorporation in an osteoporotic bone regeneration model to evaluate whether Sr could assist in regeneration outcomes. In vitro readout suggested that Sr-incorporated MSC scaffolds could enhance the expression level of osteogenic and angiogenic markers of osteoporotic bone mesenchymal stem cells (OVX BMSCs). Animal experiments showed a larger new bone area; in particular, there was a tendency for blood vessel formation to be enhanced in the Sr-MSC scaffold group, showing its positive osteogenic capacity in bone regeneration. This study systematically illustrated the effective delivery of a low-cost therapeutic Sr agent in an osteoporotic model and provided new insight into the treatment of bone defects in osteoporosis patients.

对于因外伤、先天性疾病或肿瘤而导致骨折或缺陷的患者，骨组织工程已成为一种很有前景的替代疗法。然而，结合骨质疏松症的骨缺损重建仍然是临床医生和研究人员面临的巨大挑战。根据我们之前的研究，Ca-Si 基生物陶瓷 (MSCs) 在正常条件下显示出增强的骨形成能力，并且证明锶在改善骨质疏松症患者的骨质量方面具有治疗作用。因此，在本研究中，我们试图扩大在骨质疏松骨再生模型中掺入 Sr 的 MSCs 的应用范围，以评估 Sr 是否有助于再生结果。体外读数表明，掺入 Sr 的 MSC 支架可以提高骨质疏松性骨间充质干细胞 (OVX BMSC) 的成骨和血管生成标志物的表达水平。动物实验显示新骨面积更大；特别是，Sr-MSC 支架组的血管形成有增强的趋势，表明其在骨再生中具有积极的成骨能力。这项研究系统地说明了在骨质疏松症模型中有效递送低成本治疗性 Sr 剂，并为骨质疏松症患者骨缺损的治疗提供了新的见解。显示其在骨再生中的积极成骨能力。这项研究系统地说明了在骨质疏松症模型中有效递送低成本治疗性 Sr 剂，并为骨质疏松症患者骨缺损的治疗提供了新的见解。显示其在骨再生中的积极成骨能力。这项研究系统地说明了在骨质疏松症模型中有效递送低成本治疗性 Sr 剂，并为骨质疏松症患者骨缺损的治疗提供了新的见解。